Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

34.10
+0.45001.34%
Volume:49.74K
Turnover:1.69M
Market Cap:7.04B
PE:-12.10
High:34.24
Open:34.10
Low:33.72
Close:33.65
52wk High:45.42
52wk Low:15.95
Shares:206.40M
Float Shares:89.57M
Volume Ratio:0.25
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8178
EPS(LYR):-2.7716
ROE:-80.10%
ROA:-46.73%
PB:9.57
PE(LYR):-12.30

Loading ...

Sep 04, 2026

Major Issues Report

Form 8-K - Current report
Aug 14, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Aug 06, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 06, 2026

Major Issues Report

Form 8-K - Current report
Jun 26, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 26, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 26, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 26, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 16, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 28, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 20, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 20, 2026

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
May 20, 2026

Major Issues Report

Form 8-K - Current report
May 01, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 10, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 06, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 06, 2026

Major Issues Report

Form 8-K - Current report
Dec 12, 2025

Major Issues Report

Form 8-K - Current report
Dec 11, 2025

Major Issues Report

Form 8-K - Current report
Dec 11, 2025

[Supp]Public Prospectus

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses